Pharma Focus Asia
KP - Choose our fully recyclable blister films

Moderna and Merck Developed Novel mRNA-4157/V940, Personalised mRNA Cancer Vaccine

Moderna and Merck developed mRNA-4157/V940, an investigational personalised mRNA cancer vaccine in combination with KEYTRUDA® (pembrolizumab) for the treatment of high-risk melanoma following complete resection.

The combination of mRNA-4157/V940 with KEYTRUDA demonstrated efficacy in an investigational mRNA cancer treatment for the first time in a randomised clinical trial and has resulted a potentially new frontier for the treatment of melanoma and other cancers.

mRNA- 157/V9 0 consists of a single synthetic mRNA encoding up to 34 neoantigens designed and produced using the unique mutational signature of a given patient's tumour. After injection, vaccine neoantigen sequences are endogenously translated to undergo natural cellular antigen processing and presentation.

Personalised cancer vaccines are developed to boost the patients immune system so that they can develop a anti-tumour response specific to the tumour's mutational characteristics.

KEYTRUDA is an immunotherapy which increases the body's immune system's and consists of the ability to help identify and fight tumour cells.

U.S. FDA has granted breakthrough therapy designation for mRNA-4157/V940, a personalised mRNA cancer vaccine, in combination With KEYTRUDA® (pembrolizumab).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024